{
  "attach_pages": "6",
  "attach_size": "618",
  "attach_type": "0",
  "attach_url": "https://pdf.dfcfw.com/pdf/H3_AP201711010995193609_1.pdf?1509549524000.pdf",
  "company_code": "80114781",
  "eitime": "2017-11-01 09:53:56",
  "extend": {},
  "info_code": "AP201711010995193609",
  "language": "0",
  "notice_date": "2017-11-01 00:00:00",
  "notice_title": "点评：业绩受合营联营企业拖累，长期受益于两票制、一致性评价推进",
  "page_size": 1,
  "page_size_ch": 0,
  "page_size_cht": 0,
  "page_size_en": 0,
  "rating": "A",
  "researcher": "张金洋,缪牧一",
  "security": [
    {
      "market_uni": "1",
      "publish_relation": [
        {
          "originalCode": "1042",
          "publishName": "医药商业"
        }
      ],
      "short_name": "上海医药",
      "short_name_ch": "上海医药",
      "short_name_cht": "上海醫藥",
      "short_name_en": "SHANGHAI PHARMA",
      "stock": "601607"
    }
  ],
  "short_name": "上海医药",
  "source_sample_name": "东兴证券",
  "star": "1"
}